ADC Therapeutics is a commercial-stage oncology company focused entirely on ZYNLONTA (loncastuximab tesirine), an antibody-drug conjugate (ADC) approved in the U.S. for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior lines of therapy. ZYNLONTA targets CD19, a protein expressed on B-cell tumors, and delivers a DNA-damaging payload directly to cancer cells. ADC Therapeutics sells ZYNLONTA in the U.S. through its own commercial organization across academic and community oncology settings, with distribution via wholesale distributors. Outside the U.S., the company licenses ZYNLONTA to partners: Sobi covers Europe and most ex-U.S. territories, a joint venture with Overland Pharmaceuticals covers China and certain Asian markets, and TPC covers Japan. The company earns royalties from these partners in addition to U.S. product revenue. ADC Therapeutics also has a royalty financing arrangement with HealthCare Royalty Partners, which provided $300M in gross proceeds in exchange for a 7% royalty on worldwide ex-China net sales. The company's growth strategy centers on label expansion: the Phase 3 LOTIS-5 trial is testing ZYNLONTA combined with rituximab in second-line DLBCL, with topline data expected in the first half of 2026, while LOTIS-7 is evaluating ZYNLONTA combined with Roche's bispecific antibody glofitamab, with early data showing an 89.8% overall response rate. ADC Therapeutics does not own manufacturing facilities and relies on contract manufacturers for drug production.